TickerTalks
Browse all tickers →
TickerTalks›$LFCR
LFLFCR

Lifecore Biomedical, Inc.

$LFCR·$242M·Drug Manufacturers - Specialty & Generic·Healthcare
$6.38-0.9%YTD-21.1%1Y-2.3%
Price updated 8h ago·X counts updated 5d ago
LFLFCR
$LFCRLifecore Biomedical, Inc.
$6.38-0.93%14 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $LFCR on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

14X posts · last 7 days
Sep 29Oct 11

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $LFCR — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventEvent coming upAI verdict · as of 2026-10-03

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Lifecore Biomedical take-private at $6.28 — three fairness investigations and Legion Partners 13D/A will frame the arbitrage.

Lifecore Biomedical has transitioned to a take-private arbitrage situation — the September 27 definitive merger agreement with Lifecore Inc. (Webster Equity Partners affiliate) at $6.28 per share in cash sets the deal price just below today's $6.54.

  • Three fairness-opinion investigations (Halper Sadeh, Kahn Swick & Foti, Brodsky & Smith) in late September are standard take-private theater, but Legion Partners Asset Management's September 28 13D/A amendment adds activist pressure for a potential price bump.
  • Q2 2026 EPS of -$0.19 matched consensus and Q1 revenue of $34.2M was up slightly, confirming the contract development and manufacturing business is operational — the $6.28 price reflects strategic value plus restructuring overhang.
  • At $6.54 and 54% of the 52-week range, the stock is trading 4.1% above the deal price — the market is pricing roughly 4% probability of a bump or 4% deal-break risk; sell-side 2027 EPS of -$0.88 shows standalone operations would not justify this valuation.

The near-term catalyst is any Legion Partners proxy fight or additional institutional opposition to the $6.28 price; the fairness investigations themselves rarely alter deal mechanics, but the Legion 13D/A disclosure is where arbitrage positioning gets interesting.

What to watch: Legion Partners 13D/A follow-on activity and any proxy fight disclosure; shareholder vote date and preliminary proxy filing; any competing bidder or alternative transaction proposal.

On the calendar: Q3 earnings scheduled 2026-11-03

Read the AI verdict on $LFCR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

CDMO specializing in aseptic fill-finish of sterile injectables and hyaluronic acid manufacturing for pharma and medical device customers.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $LFCR.

Drug Manufacturers - Specialty & Generic · Healthcare

Specialty pharma is bifurcating — GLP-1 adjacent programs attract premium valuations while generic manufacturers face pricing erosion from FDA approval backlogs clearing. Biosimilar launches of adalimumab (Humira), ustekinumab, and etanercept are accelerating branded erosion timelines, while mid-tier specialty pharma focuses on complex generics (ophthalmic, inhalation) to sustain margins.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+14.5%YTD
+36.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-1.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-2.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-0.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-377%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
29.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
9.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-0.19$-0.190.0%
Q1 2026May 6, 2026$-0.43$-0.24-79.2%
Q4 2025Mar 9, 2026$-0.19$-0.18-5.6%
Q3 2025Nov 6, 2025$-0.29$-0.30+3.3%
Next earningsTue, Nov 3·consensus EPS $-0.30

Forward consensus

4-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$121.5M$118.8M – $123.7M-$1.01-$1.03 – -$0.964
FY27$130.6M$128.4M – $132.9M-$0.88-$0.90 – -$0.864
FY28$150.1M$147.6M – $152.8M-$1.13-$1.16 – -$1.111
FY29$184.1M$181.0M – $187.3M-$0.52-$0.53 – -$0.512

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.51%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+25.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+14.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 34.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today4.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.985-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 9 other (8 awards · 1 inkind) in window

See when $LFCR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentSep 29SC 13D/A
8-KMaterial agreementSep 298-K — Item 1.01: Material agreement
SC 13D/AActivist amendmentSep 28SC 13D/A
AI summary

Legion Partners Asset Management and its associated funds (Legion Partners, L.P. I, Legion Partners, L.P. II, and Legion Partners, LLC) filed an amended SC 13D on Lifecore Biomedical, reflecting aggregate beneficial ownership of approximately 6,914,144 shares (17.1%) shared across Legion entities. This amended 13D was filed in the context of Lifecore's announced merger agreement with Webster Equity Partners at $6.28/share plus a CVR. Legion Partners is a known activist investor; at 17.1% ownership its position is material to the merger outcome.

8-KMaterial agreementSep 288-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

Lifecore Biomedical entered into a definitive merger agreement on September 27, 2026 with Lifecore Inc. (Parent), an affiliate of Webster Equity Partners, pursuant to which stockholders will receive $6.28 per share in cash plus one contingent value right (CVR) per share, taking the company private. The merger is structured as a back-end merger with Hazel Merger Sub merging into Lifecore, with Lifecore surviving as a wholly owned subsidiary of the Webster vehicle. This is a transformative go-private transaction; the CVR provides potential additional upside tied to future milestones.

8-KPress release / Reg FDAug 58-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Lifecore Biomedical issued its Q2 2026 earnings press release and an investor presentation on August 5, 2026, furnished as Exhibits 99.1 and 99.2 respectively. No specific revenue or earnings figures are quoted in the 8-K body; all financials are in the exhibit. Given Lifecore's announcement of a pending go-private merger at $6.28/share plus CVR (disclosed in a later 9/27/26 8-K), this Q2 earnings release serves as a final standalone public financial update before deal close.

SC 13D/AActivist amendmentJul 2SC 13D/A
8-KPress release / Reg FDJul 28-K — Item 7.01: Press release / Reg FD
SC 13D/AActivist amendmentJul 2SC 13D/A
+ 8 other (2 proxys · 2 10-Qs · 2 13Gs · 2 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Lifecore Biomedical to Participate at Upcoming Industry Conferencesglobenewswire.com·10d agoAre RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?gurufocus.com·11d agoBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD)globenewswire.com·12d agoEQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- FWAC, MGLD, LFCR, and MGgurufocus.com·14d agoHalper Sadeh LLC is Investigating Whether LFCR and SSTI are Obtaining Fair Deals for their Shareholdersglobenewswire.com·16d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$PCRX$TEVA$ACB$ZTS$ZYBT$ELAN$EVO$INDV
Voices on X · last 7 days

No standout posts about $LFCR on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport